![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF)
|
|
|
Reported by Jules Levin
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 17-20, 2011, Rome, Italy
R Campo1, E DeJesus2, H Khanlou3, H Wang4, K White4,
L Dau4, J Flaherty4, and T Fralich4
1Univ of Miami Sch of Med, Miami, FL, USA;
2Orlando Immunology Ctr, Orlando, FL, USA;
3AIDS Healthcare Foundation, Los Angeles, CA, USA;
4Gilead Sciences, Inc., Foster City, CA, USA
![rome1.gif](../images/072211/072211-1/rome1.gif)
![rome2.gif](../images/072211/072211-1/rome2.gif)
![rome3.gif](../images/072211/072211-1/rome3.gif)
![rome4.gif](../images/072211/072211-1/rome4.gif)
![rome5.gif](../images/072211/072211-1/rome5.gif)
![rome6.gif](../images/072211/072211-1/rome6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|